Potential of non-FDG PET radiotracers for paediatric patients with solid tumours

Leonor Teles , Nelleke Tolboom , Sabine L.A. Plasschaert , Alex J. Poot , Arthur J.A.T. Braat , Max M. van Noesel
{"title":"Potential of non-FDG PET radiotracers for paediatric patients with solid tumours","authors":"Leonor Teles ,&nbsp;Nelleke Tolboom ,&nbsp;Sabine L.A. Plasschaert ,&nbsp;Alex J. Poot ,&nbsp;Arthur J.A.T. Braat ,&nbsp;Max M. van Noesel","doi":"10.1016/j.ejcped.2024.100203","DOIUrl":null,"url":null,"abstract":"<div><div>Molecular imaging with positron emission tomography (PET) offers significant potential for improving diagnostic accuracy, staging and treatment monitoring in paediatric solid tumours, by using radiopharmaceuticals more specific than [<sup>18</sup>F]fluorodeoxyglucose ([<sup>18</sup>F]FDG). While non-[<sup>18</sup>F]FDG tracers have already improved diagnostic abilities in adult solid cancers such as prostate and neuroendocrine tumours, their use in the paediatric population has been underexplored. This narrative review summarises clinical evidence regarding the use, advantages, and limitations of these more specific PET tracers in paediatric patients. In neuroblastoma, [<sup>18</sup>F]mFBG, [<sup>18</sup>F]F-DOPA, and SSTR-targeting peptides stand out as the most evolved and promising tracers for the clinical setting, with encouraging results regarding feasibility, safety and detection rates. SSTR-targeting peptides have also consistently outperformed other imaging methods (both conventional and functional) and carry the benefits of theragnostic applications. For brain tumours, amino acid-based tracers in general stand out due to their ability to surpass the blood-brain barrier/blood-tumour barrier (BBB/BTB) and their specific accumulation in malignant tissue. Other paediatric solid tumours, such as sarcoma and bone tumours, suffer from a clear lack of clinical evidence that should be addressed in the near future. The studies performed to date show high accuracy, evident prognostic value, and significant clinical impact of non-[<sup>18</sup>F]FDG tracers in paediatric patients with solid tumours. However, prospective studies with longer follow-up times are warranted to provide high-level evidence regarding the impact of these tracers on patient management and prognosis, to consolidate the encouraging results obtained so far. Further research and international collaboration will be essential to overcome current challenges related to low incidence of paediatric solid tumours, logistical barriers and concerns about radiation exposure.</div></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"4 ","pages":"Article 100203"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJC paediatric oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772610X24000631","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Molecular imaging with positron emission tomography (PET) offers significant potential for improving diagnostic accuracy, staging and treatment monitoring in paediatric solid tumours, by using radiopharmaceuticals more specific than [18F]fluorodeoxyglucose ([18F]FDG). While non-[18F]FDG tracers have already improved diagnostic abilities in adult solid cancers such as prostate and neuroendocrine tumours, their use in the paediatric population has been underexplored. This narrative review summarises clinical evidence regarding the use, advantages, and limitations of these more specific PET tracers in paediatric patients. In neuroblastoma, [18F]mFBG, [18F]F-DOPA, and SSTR-targeting peptides stand out as the most evolved and promising tracers for the clinical setting, with encouraging results regarding feasibility, safety and detection rates. SSTR-targeting peptides have also consistently outperformed other imaging methods (both conventional and functional) and carry the benefits of theragnostic applications. For brain tumours, amino acid-based tracers in general stand out due to their ability to surpass the blood-brain barrier/blood-tumour barrier (BBB/BTB) and their specific accumulation in malignant tissue. Other paediatric solid tumours, such as sarcoma and bone tumours, suffer from a clear lack of clinical evidence that should be addressed in the near future. The studies performed to date show high accuracy, evident prognostic value, and significant clinical impact of non-[18F]FDG tracers in paediatric patients with solid tumours. However, prospective studies with longer follow-up times are warranted to provide high-level evidence regarding the impact of these tracers on patient management and prognosis, to consolidate the encouraging results obtained so far. Further research and international collaboration will be essential to overcome current challenges related to low incidence of paediatric solid tumours, logistical barriers and concerns about radiation exposure.
非 FDG PET 放射性示踪剂在儿科实体瘤患者中的应用潜力
正电子发射断层扫描(PET)分子成像技术通过使用比[18F]氟脱氧葡萄糖([18F]FDG)更具特异性的放射性药物,为提高儿科实体瘤的诊断准确性、分期和治疗监测提供了巨大的潜力。虽然非[18F]FDG示踪剂已经提高了前列腺癌和神经内分泌肿瘤等成人实体瘤的诊断能力,但它们在儿科人群中的应用还未得到充分探索。本叙述性综述总结了有关这些更具特异性的 PET 示踪剂在儿科患者中的使用、优势和局限性的临床证据。在神经母细胞瘤中,[18F]mFBG、[18F]F-DOPA 和 SSTR 靶向肽是最先进、最有临床应用前景的示踪剂,在可行性、安全性和检测率方面都取得了令人鼓舞的结果。SSTR 靶向肽的表现也一直优于其他成像方法(包括传统成像和功能成像),并具有治疗诊断应用的优势。对于脑肿瘤而言,氨基酸示踪剂因其能够超越血脑屏障/血瘤屏障(BBB/BTB)以及在恶性组织中的特异性蓄积而脱颖而出。其他儿科实体瘤,如肉瘤和骨肿瘤,则明显缺乏临床证据,应在不久的将来加以解决。迄今为止进行的研究表明,非[18F]FDG 示踪剂在儿科实体瘤患者中具有较高的准确性、明显的预后价值和显著的临床影响。然而,有必要进行随访时间更长的前瞻性研究,以提供有关这些示踪剂对患者管理和预后影响的高级证据,巩固迄今为止取得的令人鼓舞的成果。进一步的研究和国际合作对于克服当前与儿童实体瘤发病率低、后勤障碍和对辐射照射的担忧有关的挑战至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信